How does insulin resistance arise, and how does it cause disease? Human genetic lessons

European Journal of Endocrinology

Volumn 174, Issue 5, 2016, Pages R209-R223

  Semple, R K ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY LIVER; FEMALE; GENETICS; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; METABOLISM; NEOPLASM; OBESITY; OVARY POLYCYSTIC DISEASE;

FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; METABOLIC DISEASES; NEOPLASMS; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84970006336     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-15-1131     Document Type: Review

References (96)

1. Himsworth HP. Insulin deficiency and insulin inefficiency. BMJ 1940 1 719-722. (doi:10.1136/bmj.1.4139.719).
2. Yalow RS & Berson SA. Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determinations by a new sensitive immunoassay technic. Diabetes 1960 9 254-260. (doi:10.2337/diab.9.4.254).
3. Karam JH, Grodsky GM & Forsham PH. Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 1963 12 197-204. (doi:10.2337/diab.12.3.197).
4. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiological Reviews 1995 75 473-486. (doi:10.1002/dmr.5610090503).
5. Hanson RL, Imperatore G, Bennett PH & Knowler WC. Components of the "metabolic syndrome" and incidence of type 2 diabetes. Diabetes 2002 51 3120-3127. (doi:10.2337/diabetes.51.10.3120).
6. Utzschneider KM & Kahn SE. Review: The role of insulin resistance in nonalcoholic fatty liver disease. Journal of Clinical Endocrinology and Metabolism 2006 91 4753-4761. (doi:10.1210/jc.2006-0587).
7. Dunaif A, Segal KR, Futterweit W & Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989 38 1165-1174. (doi:10.2337/diab.38.9.1165).
8. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews. Cancer 2008 8 915-928. (doi:10.1038/nrc2536).
9. Freychet P, Roth J & Neville DM Jr. Insulin receptors in the liver: specific binding of (125I)insulin to the plasma membrane and its relation to insulin bioactivity. PNAS 1971 68 1833-1837. (doi:10.1073/pnas.68.8.1833).
10. Yip CC, Yeung CW & Moule ML. Photoaffinity labeling of insulin receptor of rat adiopocyte plasma membrane. Journal of Biological Chemistry 1978 253 1743-1745.
11. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985 313 756-761. (doi:10.1038/313756a0).
12. Taniguchi CM, Emanuelli B & Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nature Reviews. Molecular Cell Biology 2006 7 85-96. (doi:10.1038/nrm1837).
13. Cohen P. The twentieth century struggle to decipher insulin signalling. Nature Reviews. Molecular Cell Biology 2006 7 867-873. (doi:10.1038/nrm2043).
14. Whiteman EL, Cho H & Birnbaum MJ. Role of Akt/protein kinase B in metabolism. Trends in Endocrinology and Metabolism 2002 13 444-451. (doi:10.1016/S1043-2760(02)00662-8).
15. Humphrey SJ, James DE & Mann M. Protein phosphorylation: A major switchmechanismformetabolic regulation. Trends in Endocrinology and Metabolism 2015 26 676-687. (doi:10.1016/j.tem.2015.09.013).
16. McGarry JD. What ifMinkowski had been ageusic? An alternative angle on diabetes Science 1992 258 766-770. (doi:10.1126/science.1439783).
17. Muniyappa R, Lee S, Chen H & Quon MJ. Current approaches for assessing insulin sensitivity and resistance in vivo: Advantages, limitations, and appropriate usage. American Journal of Physiology - Endocrinology and Metabolism 2008 294 E15-E26. (doi:10.1152/ajpendo.00645.2007).
18. Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, Martinez- Abundis E, Ramos-Zavala MG, Hernandez-Gonzalez SO, Jacques- Camarena O & Rodriguez-Moran M. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. Journal of Clinical Endocrinology and Metabolism 2010 95 3347-3351. (doi:10.1210/jc.2010-0288).
19. Finucane FM, Luan J, Wareham NJ, Sharp SJ, O'Rahilly S, Balkau B, Flyvbjerg A, Walker M, Hojlund K, Nolan JJ et al. Correlation of the leptin:adiponectin ratio with measures of insulin resistance in nondiabetic individuals. Diabetologia 2009 52 2345-2349. (doi:10.1007/s00125-009-1508-3).
20. Goldstein JL & Brown MS. The low-density lipoprotein pathway and its relation to atherosclerosis. Annual Review of Biochemistry 1977 46 897-930. (doi:10.1146/annurev.bi.46.070177.004341).
21. Yoshimasa Y, Seino S, Whittaker J, Kakehi T, Kosaki A, Kuzuya H, Imura H, Bell GI & Steiner DF. Insulin-resistant diabetes due to a point mutation that prevents insulin proreceptor processing. Science 1988 240 784-787. (doi:10.1126/science.3283938).
22. Kadowaki T, Bevins CL, Cama A, Ojamaa K, Marcus-Samuels B, Kadowaki H, Beitz L, McKeon C & Taylor SI. Two mutant alleles of the insulin receptor gene in a patient with extreme insulin resistance. Science 1988 240 787-790. (doi:10.1126/science.2834824).
23. Semple RK, Savage DB, Cochran EK, Gorden P & O'Rahilly S. Genetic syndromes of severe insulin resistance. Endocrine Reviews 2011 32 498-514. (doi:10.1210/er.2010-0020).
24. Semple RK, Savage DB, Brierley GV & O'Rahilly S. Syndromes of Severe Insulin Resistance and/or Lipodystrophy. In Genetic Diagnosis of Endocrine Disorders (Second edition), pp 307-324. Elsevier 2016. (doi:10.1016/B978-0-12-800892-8.00022-1).
25. Taylor SI, Cama A, Accili D, Barbetti F, Quon MJ, de la Luz Sierra M, Suzuki Y, Koller E, Levy-Toledano R, Wertheimer E et al. Mutations in the insulin receptor gene. Endocrine Reviews 1992 13 566-595. (doi:10.1210/edrv-13-3-566).
26. George S, Rochford JJ, Wolfrum C, Gray SL, Schinner S, Wilson JC, Soos MA, Murgatroyd PR, Williams RM, Acerini CL et al. A family with severe insulin resistance and diabetes due to a mutation in AKT2. Science 2004 304 1325-1328. (doi:10.1126/science.1096706).
27. Dash S, Sano H, Rochford JJ, Semple RK, Yeo G, Hyden CS, Soos MA, Clark J, Rodin A, Langenberg C et al. A truncation mutation in TBC1D4 in a family with acanthosis nigricans and postprandial hyperinsulinemia. PNAS 2009 106 9350-9355. (doi:10.1073/pnas.0900909106).
28. Moltke I, Grarup N, Jorgensen ME, Bjerregaard P, Treebak JT, Fumagalli M, Korneliussen TS, Andersen MA, Nielsen TS, Krarup NT et al. A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 2014 512 190-193. (doi:10.1038/nature13425).
29. Thauvin-Robinet C, Auclair M, Duplomb L, Caron-Debarle M, Avila M, St-Onge J, LeMerrer M, Le Luyer B, Heron D, Mathieu-Dramard M et al. PIK3R1 mutations cause syndromic insulin resistance with lipoatrophy. American Journal of Human Genetics 2013 93 141-149. (doi:10.1016/j.ajhg.2013.05.019).
30. Dyment DA, Smith AC, Alcantara D, Schwartzentruber JA, Basel-Vanagaite L, Curry CJ, Temple IK, Reardon W, Mansour S, Haq MR et al. Mutations in PIK3R1 cause SHORT syndrome. American Journal of Human Genetics 2013 93 158-166. (doi:10.1016/j.ajhg.2013.06.005).
31. Chudasama KK, Winnay J, Johansson S, Claudi T, Konig R, Haldorsen I, Johansson B, Woo JR, Aarskog D, Sagen JV et al. SHORT syndrome with partial lipodystrophy due to impaired phosphatidylinositol 3 kinase signaling. American Journal of Human Genetics 2013 93 150-157. (doi:10.1016/j.ajhg.2013.05.023).
32. Seip M & Trygstad O. Generalized lipodystrophy. Archives of Disease in Childhood 1963 38 447-453. (doi:10.1136/adc.38.201.447).
33. Garg A, Wilson R, Barnes R, Arioglu E, Zaidi Z, Gurakan F, Kocak N, O'Rahilly S, Taylor SI, Patel SB et al. A gene for congenital generalized lipodystrophy maps to human chromosome 9q34. Journal of Clinical Endocrinology and Metabolism 1999 84 3390-3394. (doi:10.1210/jcem.84.9.6103).
34. Agarwal AK, Arioglu E, De Almeida S, Akkoc N, Taylor SI, Bowcock AM, Barnes RI & Garg A. AGPAT2 is mutated in congenital generalized lipodystrophy linked to chromosome 9q34. Nature Genetics 2002 31 21-23. (doi:10.1038/ng880).
35. Magre J, Delepine M, Khallouf E, Gedde-Dahl T Jr, Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Bachy A et al. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nature Genetics 2001 28 365-370. (doi:10.1038/ng585).
36. Payne VA, Grimsey N, Tuthill A, Virtue S, Gray SL, Dalla Nora E, Semple RK, O'Rahilly S & Rochford JJ. The human lipodystrophy gene BSCL2/seipin may be essential for normal adipocyte differentiation. Diabetes 2008 57 2055-2060. (doi:10.2337/db08-0184).
37. Szymanski KM, Binns D, Bartz R, Grishin NV, Li WP, Agarwal AK, Garg A, Anderson RG & Goodman JM. The lipodystrophy protein seipin is found at endoplasmic reticulum lipid droplet junctions and is important for droplet morphology. PNAS 2007 104 20890-20895. (doi:10.1073/pnas.0704154104).
38. Boutet E, El Mourabit H, Prot M, Nemani M, Khallouf E, Colard O, Maurice M, Durand-Schneider AM, Chretien Y, Gres S et al. Seipin deficiency alters fatty acid Delta9 desaturation and lipid droplet formation in Berardinelli-Seip congenital lipodystrophy. Biochimie 2009 91 796-803. (doi:10.1016/j.biochi.2009.01.011).
39. Kim CA, Delepine M, Boutet E, El Mourabit H, Le Lay S, Meier M, Nemani M, Bridel E, Leite CC, Bertola DR et al. Association of a homozygous nonsense caveolin-1 mutation with Berardinelli-Seip congenital lipodystrophy. Journal of Clinical Endocrinology and Metabolism 2008 93 1129-1134. (doi:10.1210/jc.2007-1328).
40. Hayashi YK, Matsuda C, Ogawa M, Goto K, Tominaga K, Mitsuhashi S, Park YE, Nonaka I, Hino-Fukuyo N, Haginoya K et al. Human PTRF mutations cause secondary deficiency of caveolins resulting in muscular dystrophy with generalized lipodystrophy. Journal of Clinical Investigation 2009 119 2623-2633. (doi:10.1172/JCI38660).
41. Payne F, Lim K, Girousse A, Brown RJ, Kory N, Robbins A, Xue Y, Sleigh A, Cochran E, Adams C et al. Mutations disrupting the Kennedy phosphatidylcholine pathway in humans with congenital lipodystrophy and fatty liver disease. PNAS 2014 111 8901-8906. (doi:10.1073/pnas.1408523111).
42. Shackleton S, Lloyd DJ, Jackson SN, Evans R, Niermeijer MF, Singh BM, Schmidt H, Brabant G, Kumar S, Durrington PN et al. LMNA, encoding lamin A/C, is mutated in partial lipodystrophy. Nature Genetics 2000 24 153-156. (doi:10.1038/72807).
43. Rankin J & Ellard S. The laminopathies: A clinical review. Clinical Genetics 2006 70 261-274. (doi:10.1111/j.1399-0004.2006.00677.x).
44. Semple RK, Chatterjee VK & O'Rahilly S. PPAR g and human metabolic disease. Journal of Clinical Investigation 2006 116 581-589. (doi:10.1172/JCI28003).
45. Rubio-Cabezas O, Puri V, Murano I, Saudek V, Semple RK, Dash S, Hyden CS, Bottomley W, Vigouroux C, Magre J et al. Partial lipodystrophy and insulin resistant diabetes in a patient with a homozygous nonsense mutation in CIDEC. EMBO Molecular Medicine 2009 1 280-287. (doi:10.1002/emmm.200900037).
46. Gandotra S, Le Dour C, Bottomley W, Cervera P, Giral P, Reznik Y, Charpentier G, Auclair M, Delepine M, Barroso I et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. New England Journal of Medicine 2011 364 740-748. (doi:10.1056/NEJMoa1007487).
47. Yamada K, Ikegami H, Yoneda H, Miki T & Ogihara T. All patients with Werner's syndrome are insulin resistant, but only those who also have impaired insulin secretion develop overt diabetes. Diabetes Care 1999 22 2094-2095. (doi:10.2337/diacare.22.12.2094).
48. Imura H, Nakao Y, Kuzuya H, Okamoto M, Okamoto M & Yamada K. Clinical, endocrine and metabolic aspects of the Werner syndrome compared with those of normal aging. Advances in ExperimentalMedicine and Biology 1985 190 171-185. (doi:10.1007/978-1-4684-7853-2-6).
49. Diaz A, Vogiatzi MG, Sanz MM & German J. Evaluation of short stature, carbohydrate metabolism and other endocrinopathies in Bloom's syndrome. Hormone Research 2006 66 111-117. (doi:10.1159/000093826).
50. Payne F, Colnaghi R, Rocha N, Seth A, Harris J, Carpenter G, Bottomley WE, Wheeler E, Wong S, Saudek V et al. Hypomorphism in human NSMCE2 linked to primordial dwarfism and insulin resistance. Journal of Clinical Investigation 2014 124 4028-4038. (doi:10.1172/JCI73264).
51. Weedon MN, Ellard S, Prindle MJ, Caswell R, Lango Allen H, Oram R, Godbole K, Yajnik CS, Sbraccia P, Novelli G et al. An in-frame deletion at the polymerase active site of POLD1 causes a multisystem disorder with lipodystrophy. Nature Genetics 2013 45 947-950. (doi:10.1038/ng.2670).
52. Mayson SE, Parker VE, Schutta MH, Semple RK & Rickels MR. Severe insulin resistance and hypertriglyceridemia after childhood total body irradiation. Endocrine Practice 2013 19 51-58. (doi:10.4158/EP12115.OR).
53. Ablamunits V, Weisberg SP, Lemieux JE, Combs TP & Klebanov S. Reduced adiposity in ob/ob mice following total body irradiation and bone marrow transplantation. Obesity 2007 15 1419-1429. (doi:10.1038/oby.2007.170).
54. Marshall JD, Maffei P, Collin GB & Naggert JK. Alstrom syndrome: genetics and clinical overview. Current Genomics 2011 12 225-235. (doi:10.2174/138920211795677912).
55. Huang-Doran I, Bicknell LS, Finucane FM, Rocha N, Porter KM, Tung YC, Szekeres F, Krook A, Nolan JJ, O'Driscoll M et al. Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes. Diabetes 2011 60 925-935. (doi:10.2337/db10-1334).
56. Rauch A, Thiel CT, Schindler D, Wick U, Crow YJ, Ekici AB, van Essen AJ, Goecke TO, Al-Gazali L, Chrzanowska KH et al. Mutations in the pericentrin (PCNT) gene cause primordial dwarfism. Science 2008 319 816-819. (doi:10.1126/science.1151174).
57. Chen JH, Segni M, Payne F, Huang-Doran I, Sleigh A, Adams C, UKK Consortium UK, Savage DB, O'Rahilly S, Semple RK et al. Truncation of POC1A associated with short stature and extreme insulin resistance. Journal of Molecular Endocrinology 2015 55 147-158. (doi:10.1530/JME-15-0090).
58. Gorden P, Lupsa BC, Chong AY & Lungu AO. Is there a human model for the 'metabolic syndrome' with a defined aetiology? Diabetologia 2010 53 1534-1536. (doi:10.1007/s00125-010-1719-7).
59. Virtue S & Vidal-Puig A. It's not how fat you are, it's what you do with it that counts. PLoS Biology 2008 6 e237. (doi:10.1371/journal.pbio.0060237).
60. Shulman GI. Cellular mechanisms of insulin resistance. Journal of Clinical Investigation 2000 106 171-176. (doi:10.1172/JCI10583).
61. Danforth E Jr. Failure of adipocyte differentiation causes type II diabetes mellitus? Nature Genetics 2000 26 13. (doi:10.1038/79111).
62. Robbins AL & Savage DB. The genetics of lipid storage and human lipodystrophies. Trends in Molecular Medicine 2015 21 433-438. (doi:10.1016/j.molmed.2015.04.004).
63. Misra A, Peethambaram A & Garg A. Clinical features and metabolic and autoimmune derangements in acquired partial lipodystrophy: report of 35 cases and review of the literature. Medicine 2004 83 18-34. (doi:10.1097/01.md.0000111061.69212.59).
64. Cook JR & Semple RK. Hypoadiponectinemia - cause or consequence of human "insulin resistance"? Journal of Clinical Endocrinology and Metabolism 2010 95 1544-1554. (doi:10.1210/jc.2009-2286).
65. Ye R & Scherer PE. Adiponectin, driver or passenger on the road to insulin sensitivity? Molecular Metabolism 2013 2 133-141. (doi:10.1016/j.molmet.2013.04.001).
66. Semple RK, Soos MA, Luan J, Mitchell CS, Wilson JC, Gurnell M, Cochran EK, Gorden P, Chatterjee VK, Wareham NJ et al. Elevated plasma adiponectin in humans with genetically defective insulin receptors. Journal of Clinical Endocrinology and Metabolism 2006 91 3219-3223. (doi:10.1210/jc.2006-0166).
67. Semple RK, Halberg NH, Burling K, Soos MA, Schraw T, Luan J, Cochran EK, Dunger DB, Wareham NJ, Scherer PE et al. Paradoxical elevation of high-molecular weight adiponectin in acquired extreme insulin resistance due to insulin receptor antibodies. Diabetes 2007 56 1712-1717. (doi:10.2337/db06-1665).
68. Semple RK, Cochran EK, Soos MA, Burling KA, Savage DB, Gorden P & O'Rahilly S. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008 31 977-979. (doi:10.2337/dc07-2194).
69. Mente A, Meyre D, Lanktree MB, Heydarpour M, Davis AD, Miller R, Gerstein H, Hegele RA, Yusuf S, Anand SS et al. Causal relationship between adiponectin and metabolic traits: A Mendelian randomization study in a multiethnic population. PLoS ONE 2013 8 e66808. (doi:10.1371/journal.pone.0066808).
70. Gao H, Fall T, van Dam RM, Flyvbjerg A, Zethelius B, Ingelsson E & Hagg S. Evidence of a causal relationship between adiponectin levels and insulin sensitivity: A Mendelian randomization study. Diabetes 2013 62 1338-1344. (doi:10.2337/db12-0935).
71. Yaghootkar H, Lamina C, Scott RA, Dastani Z, Hivert MF, Warren LL, Stancakova A, Buxbaum SG, Lyytikainen LP, Henneman P et al. Mendelian randomization studies do not support a causal role for reduced circulating adiponectin levels in insulin resistance and type 2 diabetes. Diabetes 2013 62 3589-3598. (doi:10.2337/db13-0128).
72. Bueno AC, Sun K, Martins CS, Elias Junior J, Miranda W, Tao C, Foss-Freitas MC, Barbieri MA, Bettiol H, de Castro M et al. A novel ADIPOQ mutation (p.M40K) impairs assembly of high-molecularweight adiponectin and is associated with early-onset obesity and metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2014 99 E683-E693. (doi:10.1210/jc.2013-3009).
73. Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, Vottero A, Kanabar D, Charlton-Menys V, Durrington P et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. Journal of Clinical Investigation 2009 119 315-322.
74. Lambert JE, Ramos-Roman MA, Browning JD & Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014 146 726-735. (doi:10.1053/j.gastro.2013.11.049).
75. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD & Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. Journal of Clinical Investigation 2005 115 1343-1351. (doi:10.1172/JCI23621).
76. Brown MS & Goldstein JL. Selective versus total insulin resistance: A pathogenic paradox. Cell Metabolism 2008 7 95-96. (doi:10.1016/j.cmet.2007.12.009).
77. Wan M, Leavens KF, Saleh D, Easton RM, Guertin DA, Peterson TR, Kaestner KH, Sabatini DM & Birnbaum MJ. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metabolism 2011 14 516-527. (doi:10.1016/j.cmet.2011.09.001).
78. Leavens KF, Easton RM, Shulman GI, Previs SF & Birnbaum MJ. Akt2 is required for hepatic lipid accumulation in models of insulin resistance. Cell Metabolism 2009 10 405-418. (doi:10.1016/j.cmet.2009.10.004).
79. Cook JR, Langlet F, Kido Y & Accili D. Pathogenesis of selective insulin resistance in isolated hepatocytes. Journal of Biological Chemistry 2015 290 13972-13980. (doi:10.1074/jbc.M115.638197).
80. Parker VE, Savage DB, O'Rahilly S & Semple RK. Mechanistic insights into insulin resistance in the geneticera. Diabetic Medicine 2011 28 1476-1486. (doi:10.1111/j.1464-5491.2011.03463.x).
81. Nandi A, Chen Z, Patel R & Poretsky L. Polycystic ovary syndrome. Endocrinology and Metabolism Clinics of North America 2014 43 123-147. (doi:10.1016/j.ecl.2013.10.003).
82. Goodarzi MO, Dumesic DA, Chazenbalk G & Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nature Reviews. Endocrinology 2011 7 219-231. (doi:10.1038/nrendo.2010.217).
83. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocrine Reviews 1997 18 774-800. (doi:10.1210/er.18.6.774).
84. Poretsky L, Seto-Young D, Shrestha A, Dhillon S, Mirjany M, Liu HC, Yih MC & Rosenwaks Z. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. Journal of Clinical Endocrinology and Metabolism 2001 86 3115-3119. (doi:10.1210/jcem.86.7.7617).
85. O'Reilly M, Gathercole L, Capper F, Arlt W & Tomlinson J. Effect of insulin on AKR1C3 expression in female adipose tissue: in-vivo and in-vitro study of adipose androgen generation in polycystic ovary syndrome. Lancet 2015 385 S16-950. (doi:10.1016/S0140-6736(15)60331-2).
86. Weber DR, Stanescu DE, Semple R, Holland C & Magge SN. Continuous subcutaneous IGF-1 therapy via insulin pump in a patient with Donohue syndrome. Journal of Pediatric Endocrinology & Metabolism 2014 27 1237-1241. (doi:10.1515/jpem-2013-0402).
87. Brisigotti M, Fabbretti G, Pesce F, Gatti R, Cohen A, Parenti G & Callea F. Congenital bilateral juvenile granulosa cell tumor of the ovary in leprechaunism: A case report. Pediatric Pathology 1993 13 549-558. (doi:10.3109/15513819309048242).
88. Stubbs SA, Webber LJ, Stark J, Rice S, Margara R, Lavery S, Trew GH, Hardy K & Franks S. Role of insulin-like growth factors in initiation of follicle growth in normal and polycystic human ovaries. Journal of Clinical Endocrinology and Metabolism 2013 98 3298-3305. (doi:10.1210/jc.2013-1378).
89. Poretsky L, Cataldo NA, Rosenwaks Z & Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocrine Reviews 1999 20 535-582. (doi:10.1210/edrv.20.4.0374).
90. Kaltsas GA, Androulakis II, Tziveriotis K, Papadogias D, Tsikini A, Makras P, Dimitriou K, Stathopoulou A & Piaditis G. Polycystic ovaries and the polycystic ovary syndrome phenotype in women with active acromegaly. Clinical Endocrinology 2007 67 917-922. (doi:10.1111/j.1365-2265.2007.02987.x).
91. Arioglu E, Andewelt A, Diabo C, Bell M, Taylor SI & Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): A 28-year perspective. Medicine 2002 81 87-100. (doi:10.1097/00005792-200203000-00001).
92. Idkowiak J, Lavery GG, Dhir V, Barrett TG, Stewart PM, Krone N & Arlt W. Premature adrenarche: novel lessons from early onset androgen excess. European Journal of Endocrinology 2011 165 189-207. (doi:10.1530/EJE-11-0223).
93. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG & Yee D. Diabetes and cancer: A consensus report. Diabetes Care 2010 33 1674-1685. (doi:10.2337/dc10-0666).
94. Nead KT, Sharp SJ, Thompson DJ, Painter JN, Savage DB, Semple RK, Barker A, Australian National Endometrial Cancer Study Group, Perry JR, Attia J et al. Evidence of a causal association between insulinemia and endometrial cancer: A mendelian randomization analysis. Journal of the National Cancer Institute 2015 107 djv178. (doi:10.1093/jnci/djv178).
95. Safar Zadeh E, Lungu AO, Cochran EK, Brown RJ, Ghany MG, Heller T, Kleiner DE & Gorden P. The liver diseases of lipodystrophy: The longterm effect of leptin treatment. Journal of Hepatology 2013 59 131-137. (doi:10.1016/j.jhep.2013.02.007).
96. Belfiore A & Malaguarnera R. Insulin receptor and cancer. Endocrine- Related Cancer 2011 18 R125-R147. (doi:10.1530/ERC-11-0074).